Comment: The structure for tibremciclib was obtained from proposed INN list 129 (August 2023) where it is described as a cyclin-dependent kinase inhibitor and antineoplastic agent. From patent analysis it appears to be a dual CDK4/6 inhibitor, a mechanism that is validated as a cancer therapy. CDK4/6 inhibition blocks the cell cycle at G1 phase and inhibits tumour cell proliferation.
|
|
2D Structure
|
|
Physico-chemical Properties
|
|
Hydrogen bond acceptors
|
8
|
Hydrogen bond donors
|
1
|
Rotatable bonds
|
6
|
Topological polar surface area
|
71.19
|
Molecular weight
|
518.61
|
XLogP
|
0.91
|
No. Lipinski's rules broken
|
1
|
Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
|
SMILES / InChI / InChIKey
|
|
Canonical SMILES
|
CCN1CCN(CC1)CC2=CC=C(N=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C6CCC[C@@H](C)N56)F
|
Isomeric SMILES
|
C(C)N1CCN(CC1)CC=2C=CC(=NC2)NC3=NC=C(C(=N3)C=4C=C(C5=C(N6C(=N5)CCC[C@H]6C)C4)F)F
|
InChI
|
InChI=1S/C28H32F2N8/c1-3-36-9-11-37(12-10-36)17-19-7-8-24(31-15-19)33-28-32-16-22(30)26(35-28)20-13-21(29)27-23(14-20)38-18(2)5-4-6-25(38)34-27/h7-8,13-16,18H,3-6,9-12,17H2,1-2H3,(H,31,32,33,35)/t18-/m1/s1
|
InChI Key
|
XOJPAVACYRFOBK-GOSISDBHSA-N
|
Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
|
|